A Case: Optimal Treatment of Hyperosmolar Hyperglycemic State (HHS)

Zamri, Aywar; oktaliani, Rahayu; bang, Herlam

doi:10.33425/2639-9326.1061

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with DM tend to increasingly suffer from infections, such as pneumonia (Polat et al, 2017), a disease caused by an infection in the lungs . Moreover, it is reported that a patient diagnosed with a hyperosmolar hyperglycemic state (HHS) is caused by bronchopneumonia infection; this disease is an acute hyperglycemic condition in type 2 DM (Zamri et al, 2020). Another study has discovered a relationship between DM and mortality of pneumonia patients at Dr. Kariadi Government General Hospital, Semarang (Pitaloka & Wibisono, 2015).…”

Section: Demographics Of Research Subjectsmentioning

confidence: 99%

Cost-effectiveness analysis of metformin and metformin-glimepiride in patients with type 2 diabetes at nene mallomo sidrap general hospital

2022

View full text Add to dashboard Cite

Metformin and metformin-glimepiride are cost-effective therapy options and are most commonly prescribed to treat type 2 diabetes mellitus (DM). This study aims to determine the cost-effectiveness of using metformin and metformin-glimepiride in patients with type 2 DM at Nene Mallomo General Hospital, Sidenreng Rappang. This analytical descriptive observational research employed a retrospective cohort design. The data of type 2 DM patients, new and old patients, were obtained from the medical record unit. The target population was data of outpatients for the period January-December 2019. The parameter of the therapeutic effectiveness is the random blood sugar levels of the patients after receiving treatment. The data on cost from the hospital perspective were obtained from the administration and finance unit. Cost-effectiveness analysis employed calculations of the average cost-effectiveness ratio (ACER) and the incremental cost-effectiveness ratio (ICER). Meanwhile, the risk ratio (RR) employed the analytical Chi-squared method to determine the relationship between the two types of therapies and their effectiveness. This study has revealed that 30 patients met the inclusion criteria; 14 patients received metformin therapy and 16 patients received metformin-glimepiride therapy. Metformin therapy is more effective (64.29%) and more costly (IDR120,736). The metformin's ACER value is 1877.99, and its ICER value is -3107.26. The cost-effectiveness analysis has revealed that metformin therapy is more cost-effective than metformin-glimepiride therapy. Meanwhile, the Chi-squared analysis has discovered no relationship between the two therapies and their effectiveness. The RR value of 1.080 concludes that metformin has 1.080 as much therapeutic effectiveness as the metformin-glimepiride.This is an open access article under the CC-BY-SA license.

show abstract

Section: Demographics Of Research Subjectsmentioning

confidence: 99%